All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2009-018240-23 | A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma | 2013-06-17 | due-trials |
| Exempt, with results | 2011-004250-26 | A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients with gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor | 2019-03-27 | not-yet-due |
| Exempt, with results | 2011-005215-86 | A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-small Cell Lung Cancer (NSCLC) | 2018-08-16 | not-yet-due |
| Ongoing, reported early | 2013-000517-20 | A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2013-000518-39 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serou... | 2022-07-07 | bad-data |
| Reported results | 2013-003874-29 | A single arm, open-label, phase 2 study to assess the efficacy and safety of lucitanib given orally as a single agent to patients with advanced/metastatic lung cancer and FGF, VEGF, or PDGF related ge... | 2016-07-28 | due-trials |
| Reported results | 2013-005532-23 | TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO 1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) | 2019-08-27 | due-trials |
| Reported results | 2014-000370-19 | TIGER-1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 2017-07-03 | due-trials |
| Reported results | 2014-003437-26 | TIGER-3: A Phase 3, Open-Label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Canc... | 2018-03-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-000816-14 | ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, ... | 2022-09-16 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-003162-13 | TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency | 2021-07-27 | bad-data |
| Listed as ongoing, but also has a completion date | 2016-003163-20 | TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homolog... | 2024-08-08 | bad-data |
| Reported results | 2017-004166-10 | A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma | 2020-01-15 | due-trials |
| Ongoing | 2017-004557-17 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platin... | not-yet-due | |
| Not reported | 2019-002980-81 | LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor | 2023-01-26 | due-trials |
| Reported results | 2020-001538-37 | CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy with Rucaparib | 2023-02-10 | due-trials |